当前位置：
X-MOL 学术
›
J. Thorac. Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Sustained Response to Crizotinib After Resistance to First-Line Alectinib Treatment in Two Patients With ALK-Rearranged NSCLC.
Journal of Thoracic Oncology ( IF 21.0 ) Pub Date : 2020-09-01 , DOI: 10.1016/j.jtho.2020.01.003 Jing Zheng 1 , Wenjia Sun 1 , Wenhong Chen 2 , Jianying Zhou 1 , Jianya Zhou 1
中文翻译：
两名ALK重排NSCLC患者对一线伊乐替尼治疗耐药后对克唑替尼的持续反应。
更新日期：2020-09-01
Journal of Thoracic Oncology ( IF 21.0 ) Pub Date : 2020-09-01 , DOI: 10.1016/j.jtho.2020.01.003 Jing Zheng 1 , Wenjia Sun 1 , Wenhong Chen 2 , Jianying Zhou 1 , Jianya Zhou 1
Affiliation
中文翻译：
两名ALK重排NSCLC患者对一线伊乐替尼治疗耐药后对克唑替尼的持续反应。
京公网安备 11010802027423号